Max Barker

Cardiac Dimensions, Inc. develops novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. It offers the CARILLON Mitral Contour System, a proprietary and implantable device designed to be positioned in the coronary sinus vein using cardiac catheterization techniques. The firm also offers patient enrollment, clinical testing, and medical consulting services. The company was founded by James W. Fitzsimmons and Scott Jordan Wolf in 2001 and is headquartered in Kirkland, WA.

Rotation Medical, Inc. develops treatment of rotator cuff disease. It includes a bioinductive implant and a set of disposable arthroscopic instruments that has been shown to heal tendons by inducing the growth of new tendon-like tissue. The company was founded by Thomas R. Hektner in 2009 and is headquartered in Plymouth, MN.

IlluminOss Medical, Inc. engages in the designing, developing, and marketing of orthopedic fracture repair products. The company was founded by Robert A. Rabiner and Arnold-Peter C. Weiss in 2007 and is headquartered in East Providence, RI.

Endotronix, Inc. develops wireless heart sensor technology. The firm has introduced the Cordella Heart Failure System, a comprehensive solution for heart failure management. The company was founded by Anthony I. Nunez and Harry D. Rowland in June 2007 and is headquartered in Lisle, IL.

Harvest Automation, Inc. designs and produces robotics for manual labor applications. It enables growers to create a sustainable workforce of robots working safely alongside people to increase efficiency, reliability and plant quality. The firm’s robots are powering the next innovation surge in agriculture and has engineered the first practical, scalable robots for a range of agricultural applications. The company was founded by Clara Vu, Paul E. Sandin, Charles M. Grinnell and Joseph L. Jones in 2008 and is headquartered in Billerica, MA.

Tekla Capital Management LLC is an independent, SEC-registered investment advisor headquartered in Boston, Massachusetts. Formerly known as Hambrecht & Quist Capital Management LLC, the firm serves as an investment adviser for four closed-end funds – Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund.

LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.

Occidental Chemical Corp. manufactures polyvinyl chloride resins, chlorine and caustic soda. It also offers basic chemicals, oxyvinyls, food grade and armand products. The company was founded in 1988 and is headquartered in Dallas, TX.

University of Akron provides public research education. Its programs include under graduate studies, graduate studies, international studies, law, and continuing education. The company was founded in 1870 and is headquartered in Akron, OH.

Merlin Nexus is a private equity firm founded in 2001. The firm headquartered in New York.

Seahorse Bioscience, Inc. provides metabolic analyzers and stress kits. Its medical device is use to determine a new therapeutic approach in treating acute myeloid leukemia. The company was founded on November 2, 2000 and is headquartered in Billerica, MA.

FlowCardia, Inc. designs, develops and manufactures endovascular devices. It offers flowmate Injector to optimize the performance of crosser cto recanalization and crosser catheter, a minimally-invasive endovascular device. The firm also provides portfolio of catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. The company was founded by Henry Nita and Erik T. Engelson in 2001 and is headquartered in Sunnyvale, CA.

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.

AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands.

Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.

Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona.

Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain.

LSP Management Group BV (LSP) is a venture capital subsidiary of LSP Management Group BV founded in 2006 by Martijn Kleijwegt. The firm is headquartered in Waltham, Massachusetts.

Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain.

Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain.

Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.

SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation.

ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021.

HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA.

Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation.

Methinks Software SL provides universal and timely diagnosis to enable life-saving treatments worldwide. The company is based in Barcelona, Spain. The Spanish company's first focus is on stroke, the second cause of death and a major cause of disability in the world. The company was founded by Cristian Martí. Pau Rodríguez has been the CEO of the company since 2019.

Health Economics Privak II NV is a Belgian company that provides credit intermediation services. The private company is based in De Pinte, Belgium. The company was founded in 2017.